Description:

ODM derived from http://clinicaltrials.gov/show/NCT00642941

Link:

http://clinicaltrials.gov/show/NCT00642941

Keywords:
Versions (1) ▾
  1. 12/9/13
Uploaded on:

December 9, 2013

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility NCT00642941 Sarcoma

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Inclusion Criteria
age at least 2 Years
progressive, recurrent or refractory Ewing's sarcoma, or recurrent or refractory osteosarcoma, synovial sarcoma, rhabdomyosarcoma, or other sarcomas of the following sub-types: alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcoma and myxoid liposarcoma.
Exclusion Criteria
clinically significant unrelated systemic illness which would compromise the patient's ability to tolerate the investigational agent, or interfere with the study procedures or results
known hypersensitivity to any of the components of R1507 or prior hypersensitivity reactions to monoclonal antibodies
current or previous treatment (within last 6 months) with chronic pharmacological doses of corticosteroids, immunosuppressive agents or medications that inactivate or may interfere with the pharmacological activity of R1507
current or prior therapy with IGF inhibitor (monoclonal or specific kinase inhibitor)
history of solid organ transplant
other malignant disease diagnosed within the previous 5 years, excluding intra-epithelial cervical neoplasia or non-melanoma skin cancer.